A follow-up trial in the neoadjuvant setting involving 54 HER2-positive patients with DCIS or early invasive breast cancer indicated that clinical and immune responses to the tumor did not vary significantly between different routes (intralesional versus intranodal versus intralesional-plus-intranodal) by which the same DC vaccine is administered (110). Here, ERBB2 is linked to invasive breast carcinoma.